canertinib  (BioVision)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 88
    Name:
    Canertinib CI 1033 PD 183805
    Description:
    Canertinib is an irreversible tyrosine kinase inhibitor It not only inhibits tyrosine phosphorylation but also enhances ubiquitinylation and accelerates endocytosis and subsequent intracellular destruction of ErbB 2 molecules Canertinib alkylates a cysteine residue specific to ErbB receptors The degradative pathway of ErbB receptor tyrosine kinases stimulated by tyrosine kinase inhibitors appears to be chaperone mediated and thus is similar to the pathways activated by the heat shock protein 90 Hsp90 antagonist geldanamycin and by stress induced mechanisms
    Catalog Number:
    1617-5
    Price:
    None
    Size:
    5 mg
    Category:
    Biochemicals
    Quantity:
    1
    Buy from Supplier


    Structured Review

    BioVision canertinib
    Canertinib CI 1033 PD 183805
    Canertinib is an irreversible tyrosine kinase inhibitor It not only inhibits tyrosine phosphorylation but also enhances ubiquitinylation and accelerates endocytosis and subsequent intracellular destruction of ErbB 2 molecules Canertinib alkylates a cysteine residue specific to ErbB receptors The degradative pathway of ErbB receptor tyrosine kinases stimulated by tyrosine kinase inhibitors appears to be chaperone mediated and thus is similar to the pathways activated by the heat shock protein 90 Hsp90 antagonist geldanamycin and by stress induced mechanisms
    https://www.bioz.com/result/canertinib/product/BioVision
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    canertinib - by Bioz Stars, 2020-09
    88/100 stars

    Images

    Related Articles

    Protease Inhibitor:

    Article Title: Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors
    Article Snippet: .. EGFR Tyrosine Kinase Inhibitor Set including canertinib, erlotinib hydrochloride, gefitinib, lapatinib ditosylate and PD153035 hydrochloride was purchased from BioVision Inc. Sulfo-NHS-biotin and protease inhibitor cocktail were products from Sigma. .. Plasmid constructs and transfections Small hairpin RNAs (shRNAs) targeting the coding sequence of AnxA6 in pGIPZ lentiviral vector, a non-silencing shRNA control or the empty vector (Open Biosystems Inc.), were used to transfect BT-549 and MDA-MB-231 BCCs using Lipofectamine 2000 (Invitrogen).

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 88
    BioVision pan erbb inhibitor ci 1033
    Modulation of PI3-K activity inversely impacts InlB-requirement for Lm entry in vitro. (A) Whole cell extracts from LS174T cells incubated with PBS or different concentrations of the <t>ErbB</t> inhibitor <t>CI-1033</t> (0.01, 0.1, or 1 µM) during 24 h, immunoblotted for P-Akt and total Akt. (B) Invasion assays of WT Lm EGD and isogenic mutants Δ inlA and Δ inlB in LS174T cells incubated with PBS (controls, black bars) or CI-1033 1 µM (gray bars) for 24 h. (C) Whole cell extracts from LS174T cells incubated with PBS or CI-1033 1 µM and infected with WT Lm EGD and isogenic mutant Δ inlB , immunoblotted for P-Akt and total Akt. (D) Whole cell extracts from Jar cells incubated with PBS or EGF 50 ng/ml during 10, 30, or 60 min, immunoblotted for P-Akt and total Akt. (E) Whole cell extracts from Jar cells transfected with esiRNA PTEN, immunoblotted for PTEN. (F) Whole cell extracts from Jar cells transfected with esiRNA PTEN or control scrambled and incubated with PBS or EGF 50 ng/ml for 120 min, immunoblotted for P-Akt and total Akt. (G) Invasion assays of WT Lm EGD and isogenic mutants Δ inlA and Δ inlB in Jar cells incubated with PBS, or transfected with esiRNA PTEN or incubated with EGF 50 ng/ml. (H) Invasion assays of WT Lm EGD and isogenic mutants Δ inlA and Δ inlB in Jar cells incubated with PBS or incubated with EGF 50 ng/ml, and transfected with esiRNA PTEN. (B, G, and H) Invasion assays were performed in triplicates and represent at least three independent experiments for each condition tested. Relative entry represents the ratio of CFUs for each strain divided by the mean of CFUs for the WT Lm EGD strain. A one-way ANOVA test followed by a Bonferroni’s multiple comparisons was performed. Error bars, SEM. (A, C, D, E, and F) Immunoblots were performed at least two times. Densitometry was performed and the ratio of P-Akt over total Akt is relative to the PBS, for which the value is normalized to 1.
    Pan Erbb Inhibitor Ci 1033, supplied by BioVision, used in various techniques. Bioz Stars score: 88/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pan erbb inhibitor ci 1033/product/BioVision
    Average 88 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    pan erbb inhibitor ci 1033 - by Bioz Stars, 2020-09
    88/100 stars
      Buy from Supplier

    Image Search Results


    Modulation of PI3-K activity inversely impacts InlB-requirement for Lm entry in vitro. (A) Whole cell extracts from LS174T cells incubated with PBS or different concentrations of the ErbB inhibitor CI-1033 (0.01, 0.1, or 1 µM) during 24 h, immunoblotted for P-Akt and total Akt. (B) Invasion assays of WT Lm EGD and isogenic mutants Δ inlA and Δ inlB in LS174T cells incubated with PBS (controls, black bars) or CI-1033 1 µM (gray bars) for 24 h. (C) Whole cell extracts from LS174T cells incubated with PBS or CI-1033 1 µM and infected with WT Lm EGD and isogenic mutant Δ inlB , immunoblotted for P-Akt and total Akt. (D) Whole cell extracts from Jar cells incubated with PBS or EGF 50 ng/ml during 10, 30, or 60 min, immunoblotted for P-Akt and total Akt. (E) Whole cell extracts from Jar cells transfected with esiRNA PTEN, immunoblotted for PTEN. (F) Whole cell extracts from Jar cells transfected with esiRNA PTEN or control scrambled and incubated with PBS or EGF 50 ng/ml for 120 min, immunoblotted for P-Akt and total Akt. (G) Invasion assays of WT Lm EGD and isogenic mutants Δ inlA and Δ inlB in Jar cells incubated with PBS, or transfected with esiRNA PTEN or incubated with EGF 50 ng/ml. (H) Invasion assays of WT Lm EGD and isogenic mutants Δ inlA and Δ inlB in Jar cells incubated with PBS or incubated with EGF 50 ng/ml, and transfected with esiRNA PTEN. (B, G, and H) Invasion assays were performed in triplicates and represent at least three independent experiments for each condition tested. Relative entry represents the ratio of CFUs for each strain divided by the mean of CFUs for the WT Lm EGD strain. A one-way ANOVA test followed by a Bonferroni’s multiple comparisons was performed. Error bars, SEM. (A, C, D, E, and F) Immunoblots were performed at least two times. Densitometry was performed and the ratio of P-Akt over total Akt is relative to the PBS, for which the value is normalized to 1.

    Journal: The Journal of Experimental Medicine

    Article Title: PI3-kinase activation is critical for host barrier permissiveness to Listeria monocytogenes

    doi: 10.1084/jem.20141406

    Figure Lengend Snippet: Modulation of PI3-K activity inversely impacts InlB-requirement for Lm entry in vitro. (A) Whole cell extracts from LS174T cells incubated with PBS or different concentrations of the ErbB inhibitor CI-1033 (0.01, 0.1, or 1 µM) during 24 h, immunoblotted for P-Akt and total Akt. (B) Invasion assays of WT Lm EGD and isogenic mutants Δ inlA and Δ inlB in LS174T cells incubated with PBS (controls, black bars) or CI-1033 1 µM (gray bars) for 24 h. (C) Whole cell extracts from LS174T cells incubated with PBS or CI-1033 1 µM and infected with WT Lm EGD and isogenic mutant Δ inlB , immunoblotted for P-Akt and total Akt. (D) Whole cell extracts from Jar cells incubated with PBS or EGF 50 ng/ml during 10, 30, or 60 min, immunoblotted for P-Akt and total Akt. (E) Whole cell extracts from Jar cells transfected with esiRNA PTEN, immunoblotted for PTEN. (F) Whole cell extracts from Jar cells transfected with esiRNA PTEN or control scrambled and incubated with PBS or EGF 50 ng/ml for 120 min, immunoblotted for P-Akt and total Akt. (G) Invasion assays of WT Lm EGD and isogenic mutants Δ inlA and Δ inlB in Jar cells incubated with PBS, or transfected with esiRNA PTEN or incubated with EGF 50 ng/ml. (H) Invasion assays of WT Lm EGD and isogenic mutants Δ inlA and Δ inlB in Jar cells incubated with PBS or incubated with EGF 50 ng/ml, and transfected with esiRNA PTEN. (B, G, and H) Invasion assays were performed in triplicates and represent at least three independent experiments for each condition tested. Relative entry represents the ratio of CFUs for each strain divided by the mean of CFUs for the WT Lm EGD strain. A one-way ANOVA test followed by a Bonferroni’s multiple comparisons was performed. Error bars, SEM. (A, C, D, E, and F) Immunoblots were performed at least two times. Densitometry was performed and the ratio of P-Akt over total Akt is relative to the PBS, for which the value is normalized to 1.

    Article Snippet: The pan-ErbB inhibitor CI-1033 was purchased from Biovision.

    Techniques: Activity Assay, In Vitro, Incubation, Infection, Mutagenesis, Transfection, esiRNA, Western Blot